Phase II VIRO-15 trial of olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588)

Autor: Holloway, R.W., Mendivil, A.A., Kendrick, J.E., IV, Abaid, L.N., Brown, J.V., Fitzsimmons, C.K., Kennard, J.A., King, M.M., LeBlanc, J., Lopez, K., Manyam, M., McKenzie, N.D., Mori, K.M., Smith, J.L., Stephens, A.J., Ahmad, S.
Zdroj: In Gynecologic Oncology October 2020 159 Supplement 1:60-60
Databáze: ScienceDirect
Externí odkaz: